Scientists Find New Way to ‘Print’ Living Tissue – NBCNews.com
NBCNews.com |
Scientists Find New Way to ‘Print’ Living Tissue
NBCNews.com To avoid this, the Oxford team, led by 3D-bioprinting scientist Alexander Graham from Oxford Synthetic Biology (OxSyBio), contained their cells within nanolitre droplets that were wrapped in a lipid coating. These droplets could then be placed one … Scientists 3D-print ‘high-resolution’ living tissueRT Oxford scientists develop new method to 3D print ‘high resolution’ living tissuesInternational Business Times UK |
NBCNews.com |
Scientists Find New Way to ‘Print’ Living Tissue
NBCNews.com To avoid this, the Oxford team, led by 3D-bioprinting scientist Alexander Graham from Oxford Synthetic Biology (OxSyBio), contained their cells within nanolitre droplets that were wrapped in a lipid coating. These droplets could then be placed one … Scientists 3D-print ‘high-resolution’ living tissueRT Oxford scientists develop new method to 3D print ‘high resolution’ living tissuesInternational Business Times UK |
|
Monsanto, ToolGen enter Crispr licensing pact
World Grain ST. LOUIS, MISSOURI, U.S. — Monsanto Co. and ToolGen, Inc., a Seoul, South Korea-based biotechnology company specializing in genome editing, have reached a global licensing agreement for the use of ToolGen’s Crispr technology platform to develop … |
Deccan Chronicle |
Vitamin C may encourage blood cancer stem cells to die
Science Daily Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published … High dose injections of vitamin C could help to fight blood cancer and stop it from spreading, study claimsDaily Mail Vitamin C could help to fight cancer, a study claimsExpress.co.uk Vitamin C stops blood cancer in miceSBS The Sun –PanARMENIAN.Net all 12 news articles » |
|
Cellectis Starts BPDCN Phase I Trial with Gene-Edited CAR–T Therapy
Genetic Engineering & Biotechnology News Cellectis reported that the first patient has been dosed in a Phase I clinical trial evaluating its TALEN® gene-edited CAR T-cell product UCART123 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The BPDCN study follows on from … |